Prospective Early Response Imaging Biomarker for Neoadjuvant Breast Cancer Chemotherapy
Open Access
- 15 January 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (2), 443-450
- https://doi.org/10.1158/1078-0432.ccr-06-1888
Abstract
Purpose: The American Cancer Society estimates that in 2006, 212,920 women will be diagnosed with breast cancer and that 40,970 women will die from the disease. The development of more efficacious chemotherapies has improved outcomes, but the rapid assessment of clinical benefit from these agents remains challenging. In breast cancer patients receiving neoadjuvant chemotherapy, treatment response is traditionally assessed by physical examination and volumetric-based measurements, which are subjective and require macroscopic changes in tumor morphology. In this study, we evaluate the feasibility of using diffusion magnetic resonance imaging (MRI) as a reliable and quantitative measure for the early assessment of response in a breast cancer model. Experimental Design: Mice implanted with human breast cancer (MX-1) were treated with cyclophosphamide and evaluated using diffusion MRI and growth kinetics. Histologic analyses using terminal nucleotidyl transferase–mediated nick end labeling and H&E were done on tumor samples for correlation with imaging results. Results: Cyclophosphamide treatment resulted in a significant reduction in tumor volumes compared with controls. The mean apparent diffusion change for treated tumors at days 4 and 7 posttreatment was 44 ± 5% and 94 ± 7%, respectively, which was statistically greater (P < 0.05) than the control tumors at the same time intervals. The median time-to-progression for control and treated groups was 11 and 32 days, respectively (P < 0.05). Conclusion: Diffusion MRI was shown to detect early changes in the tumor microenvironment, which correlated with standard measures of tumor response as well as overall outcome. Moreover, these findings show the feasibility of using diffusion MRI for assessing treatment response of a breast tumor model in a neoadjuvant setting.Keywords
This publication has 36 references indexed in Scilit:
- Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistanceNMR in Biomedicine, 2006
- Dynamic Imaging of Emerging Resistance during Cancer TherapyCancer Research, 2006
- Clinical and Radiologic Assessments to Predict Breast Cancer Pathologic Complete Response to Neoadjuvant ChemotherapyBreast Cancer Research and Treatment, 2005
- Diffusion imaging for evaluation of tumor therapies in preclinical animal modelsMagnetic Resonance Materials in Physics, Biology and Medicine, 2004
- Therapeutic Efficacy of DTI-015 using Diffusion Magnetic Resonance Imaging as an Early Surrogate MarkerClinical Cancer Research, 2004
- Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategyGene Therapy, 2000
- Induction of DNA crosslinks and DNA strand lesions by cyclophosphamide after activation by cytochrome P450 2B1Mutation Research, 1997
- Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6European Journal Of Cancer, 1994
- Biological factors of prognostic significance in locally advanced breast cancerBreast Cancer Research and Treatment, 1994
- MR Imaging of Anisotropically Restricted Diffusion of Water in the Nervous SystemJournal of Computer Assisted Tomography, 1991